Company InfoNewsInvestor InformationResearchDevelopmentCareersBusiness DevelopmentResourcesDrugs databaseBack to the home pageSearch  
Drugs database
Drugs A-Z

Brands A-Z

Drugs by categories

Drugs by manufacturer

Drugs by packager

Antibiotics for sale

Online Viagra bestellen in Nederland

Home / Drugs / Starting with V / Valproic Acid
 
Valproic Acid
 

A fatty acid with anticonvulsant properties used in the treatment of epilepsy. The mechanisms of its therapeutic actions are not well understood. It may act by increasing gamma-aminobutyric acid levels in the brain or by altering the properties of voltage dependent sodium channels. Typically supplied in the sodium salt form (76584-70-8). Valproic Acid is also a histone deacetylase inhibitor and is under investigation for treatment of HIV and various cancers.
BrandsAlti-Valproic
Avugane
Baceca
Convulex
Delepsine
Depacon
Depakene
Depakine
Depakote
Deproic
Dom-Valproic
Epilex
Epilim
Epival
Ergenyl
Med Valproic
Mylproin
Novo-Valproic
Nu-Valproic
Penta-Valproic
Sprinkle
Stavzor
Valcote
Valparin
CategoriesAnticonvulsants
Enzyme Inhibitors
Antimanic Agents
GABA Agents
ManufacturersBanner pharmacaps inc
Abbott laboratories pharmaceutical products div
Catalent pharma solutions llc
Par pharmaceutical inc
Rp scherer north america div rp scherer corp
Usl pharma inc
Alpharma uspd inc
Apotex inc richmond hill
High technology pharmacal co inc
Pharmaceutical assoc inc div beach products
Sun pharmaceutical industries inc
Teva pharmaceuticals usa
Vintage pharmaceuticals llc
Wockhardt eu operations (swiss) ag
PackagersAbbott Laboratories Ltd.
Apothecon
Atlantic Biologicals Corporation
Banner Pharmacaps Inc.
Bedford Labs
Ben Venue Laboratories Inc.
Caraco Pharmaceutical Labs
Cardinal Health
Catalent Pharma Solutions
Coupler Enterprises Inc.
Global Pharmaceuticals
Heartland Repack Services LLC
Hi Tech Pharmacal Co. Inc.
Impax Laboratories Inc.
Ivax Pharmaceuticals
Kaiser Foundation Hospital
Lake Erie Medical and Surgical Supply
Major Pharmaceuticals
Mckesson Corp.
Murfreesboro Pharmaceutical Nursing Supply
Noven Pharmaceuticals Inc.
Nucare Pharmaceuticals Inc.
Pharmaceutical Association
Pharmaceutical Utilization Management Program VA Inc.
Physicians Total Care Inc.
Pliva Inc.
Precision Dose Inc.
Prepackage Specialists
Prepak Systems Inc.
Professional Co.
Qualitest
Rebel Distributors Corp.
Remedy Repack
Sandoz
Teva Pharmaceutical Industries Ltd.
Tya Pharmaceuticals
UDL Laboratories
USL Pharma Inc.
Vangard Labs Inc.
Vintage Pharmaceuticals Inc.
Watson Pharmaceuticals
Wockhardt Ltd.
Xactdose Inc.
Synonyms2-propylvaleric acid
Di-n-propylacetic acid
Di-n-propylessigsaure
Dipropylacetic acid
n-DPA

indication

For treatment and management of seizure disorders, mania, and prophylactic treatment of migraine headache.

pharmacology

Valproic Acid is an anticonvulsant and mood-stabilizing drug used primarily in the treatment of epilepsy and bipolar disorder. It is also used to treat migraine headaches and schizophrenia. In epileptics, valproic acid is used to control absence seizures, tonic-clonic seizures (grand mal), complex partial seizures, and the seizures associated with Lennox-Gastaut syndrome. Valproic Acid is believed to affect the function of the neurotransmitter GABA (as a GABA transaminase inhibitor) in the human brain. Valproic Acid dissociates to the valproate ion in the gastrointestinal tract. Valproic acid has also been shown to be an inhibitor of an enzyme called histone deacetylase 1 (HDAC1). HDAC1 is needed for HIV to remain in infected cells. A study published in August 2005 revealed that patients treated with valproic acid in addition to highly active antiretroviral therapy (HAART) showed a 75% reduction in latent HIV infection.

mechanism of action

Valproic Acid binds to and inhibits GABA transaminase. The drug's anticonvulsant activity may be related to increased brain concentrations of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the CNS, by inhibiting enzymes that catabolize GABA or block the reuptake of GABA into glia and nerve endings. Valproic Acid may also work by suppressing repetitive neuronal firing through inhibition of voltage-sensitive sodium channels. It is also a histone deacetylase inhibitor.

toxicity

Oral, mouse: LD50 = 1098 mg/kg; Oral, rat: LD50 = 670 mg/kg. Symptoms of overdose may include coma, extreme drowsiness, and heart problems.

biotransformation

Valproic Acid is metabolized almost entirely by the liver. In adult patients on monotherapy, 30-50% of an administered dose appears in urine as a glucuronide conjugate. Mitochondrial ß-oxidation is the other major metabolic pathway, typically accounting for over 40% of the dose. Usually, less than 15-20% of the dose is eliminated by other oxidative mechanisms. Less than 3% of an administered dose is excreted unchanged in urine.

absorption

Rapid absorption from gastrointestinal tract.

half life

9-16 hours

route of elimination

Valproate is metabolized almost entirely by the liver. Less than 3% of an administered dose is excreted unchanged in urine. Mitochondrial ß-oxidation is the other major metabolic pathway, typically accounting for over 40% of the dose.

drug interactions

Acetylsalicylic acid: Acetylsalicylic acid increases the effect of valproic acid.

Carbamazepine: Decreases the effect of valproic acid

Clarithromycin: The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Clarithromycin is initiated, discontinued or dose changed.

Erythromycin: The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Erythromycin is initiated, discontinued or dose changed.

Felbamate: Felbamate, a CYP2C19 inhibitor, may decrease the metabolism of Valproic acid, a CYP2C19 substrate. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Felbamate is initiated, discontinued or dose changed.

Lamotrigine: Valproic acid may increase the adverse effects of Lamotrigine by increasing Lamotrigine serum concentration. The Lamotrigine dose should be reduced by 50% during concomitant therapy. Monitor for changes in Lamotrigine therapeutic and adverse effects if Valproic acid is initiated, discontinued or dose changed.

Lorazepam: Valproic acid may increase the serum concentration of Lorazepam by reducing Lorazepam metabolism. The Lorazepam dose should be reduced by 50% during concomitant therapy. Monitor for increased Lorazepam effects and toxicity.

Nimodipine: Valproic acid increases the effect of nimodipine

Rifampin: Rifampin may reduce the serum concentration of Valproic acid by increasing Valproic acid metabolism. Valproic acid dose adjustments may be required during concomitant therapy. Monitor Valproic acid serum concentrations, efficacy and toxicity if Rifampin is initiated, discontinued or dose changed.

Telithromycin: The macrolide antibiotic, Erythromycin, may increase the serum concentratin of Valproic acid. Consider alternate therapy or monitor for changes in Valproic acid therapeutic and adverse effects if Telithromycin is initiated, discontinued or dose changed.

Tipranavir: Tipranavir decreases the concentration of Valproic acid. Monitor Valproid acid efficacy.